U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C15H13ClN4O2S2.ClH
Molecular Weight 417.333
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of WAY-181187 HYDROCHLORIDE

SMILES

Cl.NCCC1=CN(C2=C1C=CC=C2)S(=O)(=O)C3=C(Cl)N=C4SC=CN34

InChI

InChIKey=YWNBHKWSECANPP-UHFFFAOYSA-N
InChI=1S/C15H13ClN4O2S2.ClH/c16-13-14(19-7-8-23-15(19)18-13)24(21,22)20-9-10(5-6-17)11-3-1-2-4-12(11)20;/h1-4,7-9H,5-6,17H2;1H

HIDE SMILES / InChI

Molecular Formula C15H13ClN4O2S2
Molecular Weight 380.872
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

WAY-181187 is a high affinity and selective 5-HT6 agonist. It displays 60-fold selectivity over other 5-HT and monoamine receptors. WAY-181187 stimulates cAMP, ERK1/2 and Fyn kinase signaling pathway through serotonin receptor activation. WAY-181187 produced both antidepressant-like and anxiolytic-like effects in the animal model. It had been in phase I clinical trial for the treatment of anxiety disorders but this research has been discontinued.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
2.2 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Discovery of N1-(6-chloroimidazo[2,1-b][1,3]thiazole-5-sulfonyl)tryptamine as a potent, selective, and orally active 5-HT(6) receptor agonist.
2007 Nov 15
Neuropharmacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466.
2008 May
Patents

Patents

Sample Use Guides

Rat: 10 mg/kg
Route of Administration: Intraperitoneal
In hippocampal slice sections, sodium azide (10 mM) treatment significantly increased glutamate (P = 0.0039) release compared with vehicle treatment. Pretreatment of WAY-181187 (0.1–10 uM) significantly and dose-dependently attenuated sodium azide-stimulated increases but did not alter basal amino-acid levels in this in vitro system. P-values comparing doses of WAY-181187 to sodium azide were as follows: glutamate - 0.1 uM, P = 0.1032; 0.3 uM, P=0.0001; 1 uM, P = 0.0492; 3 uM, P=0.0001; 10 uM, P=0.0001.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:57:11 GMT 2023
Edited
by admin
on Fri Dec 15 15:57:11 GMT 2023
Record UNII
XGK56C5380
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
WAY-181187 HYDROCHLORIDE
Common Name English
1H-INDOLE-3-ETHANAMINE, 1-((6-CHLOROIMIDAZO((2,1-B)THIAZOL-5-YL)SULFONYL)-, HYDROCHLORIDE (1:1)
Common Name English
Code System Code Type Description
CAS
554403-08-6
Created by admin on Fri Dec 15 15:57:11 GMT 2023 , Edited by admin on Fri Dec 15 15:57:11 GMT 2023
PRIMARY
PUBCHEM
22219735
Created by admin on Fri Dec 15 15:57:11 GMT 2023 , Edited by admin on Fri Dec 15 15:57:11 GMT 2023
PRIMARY
FDA UNII
XGK56C5380
Created by admin on Fri Dec 15 15:57:11 GMT 2023 , Edited by admin on Fri Dec 15 15:57:11 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY